|
Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines |
Combined Measles, Mumps, Rubella, Varicella Vaccine |
208136/040 |
|
Measles; Mumps; Rubella; Varicella |
Phase 3 |
|
|
|
|
This is a Year 2 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
February 2015 |